2023
An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Upadhayay S, Yedke N, Rahi V, Singh S, Kumar S, Arora A, Chandolia P, Kaur P, Kumar M, Koshal P, Jamwal S, Kumar P. An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development. Neurochemical Research 2023, 48: 1631-1647. PMID: 36738367, DOI: 10.1007/s11064-023-03868-1.Peer-Reviewed Original ResearchConceptsMedium spiny neuronsAnimal modelsGABAergic medium spiny neuronsDisease modelsKey clinical manifestationsHuntington's disease modelsPathogenesis of diseaseWeb of ScienceClinical manifestationsPathophysiological mechanismsSpiny neuronsPreclinical studiesMotor impairmentLike symptomsTherapeutic targetExperimental animalsExcessive productionHuntington's diseaseOxidative stressDiseasePathogenic conditionsDrug discoveryMitochondrial functionFree radicalsNeurotoxin
2020
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising targetGene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives
Jamwal S, Elsworth JD, Rahi V, Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Review Of Neurotherapeutics 2020, 20: 1123-1141. PMID: 32720531, DOI: 10.1080/14737175.2020.1801424.Peer-Reviewed Original ResearchConceptsGene therapyClinical trialsDisease-modifying therapiesMutant huntingtinTreatment of HDAntibody-based therapiesPotential therapeutic interventionsNew therapeutic targetsGene-based therapiesImmune activationClinical dataImmunotherapyTherapeutic targetFunctional restorationTherapeutic interventionsTherapyHD pathogenesisMHTT proteinRecent updatesFuture perspectivesPromising strategyTrialsCurrent statusConsiderable attentionHD
2018
Management of HD: Insight into Molecular Mechanisms and Potential Neuroprotective Drug Strategies
Kumar P, Jamwal S, Kumar A. Management of HD: Insight into Molecular Mechanisms and Potential Neuroprotective Drug Strategies. 2018, 197-206. DOI: 10.1007/978-981-13-0944-1_18.Peer-Reviewed Original ResearchManagement of HDAnti-inflammatory agentsMedium spiny neuronsHuntington's diseaseMutant huntingtin proteinPathophysiology of HDGABAergic medium spiny neuronsTreatment of HDSpecific neurodegenerative processesFuture therapeutic targetsUse of antioxidantsMolecular mechanismsBasal gangliaSpiny neuronsNeurodegenerative processesHD subjectsPathogenic mechanismsTherapeutic targetRelated pathogenesisClinical practiceRare typeNeurodegenerative disordersPathway dysregulationDrug strategiesOxidative stress